Mafoprazine is an antipsychotic of the phenylpiperazine class which is used in veterinary medicine. Intramuscular injections of mafoprazine mesylate are used for the sedation of pigs either on its own, or in combination with sodium pentobarbital or thiopental.
It demonstrates activity as a D<sub>2</sub> dopamine receptor antagonist, an ñ<sub>1</sub> adrenergic receptor antagonist, and an ñ<sub>2</sub> adrenergic receptor agonist.
The affinity of mafoprazine for D<sub>2</sub> dopamine receptors is 6 and 16 times lower than that of chlorpromazine and haloperidol, respectively, but 2 times higher than that of azaperone.
The K<sub>i</sub> for various receptors was determined using rat neuronal receptor binding assays.
Mafoprazine was first synthesized in 1988. It is sold as Mafropanî by DS Pharma Animal Health Co. Ltd., Osaka, Japan.